Why Did Valeant’s Shares Plunge Yesterday?

Jim Grant is “confidently bearish” on the company. Will his bet pay off?

| More on:
The Motley Fool

Jim Grant is one of the most respected financial minds on Wall Street. His newsletter, The Interest Rate Observer, is one of the most read publications by investment professionals. So when the most recent edition took aim at one of Canada’s highest-flying companies, Valeant Pharmaceuticals (TSX:VRX)(NYSE:VRX), it’s no surprise that the company’s shares plunged over 5% in response.

Mr. Grant referred to Valeant as a “financialized pharma company” that he is “confidently bearish on.” He even cited legendary short seller Jim Chanos for the idea. Mr. Chanos is most famous for shorting the shares of Enron right before its collapse.

There were some interesting arguments made by Mr. Grant. First of all, as is well-known, Valeant is a serial acquirer. As a result, the company only spends about 2.7% of sales on research and development. Meanwhile, industry leaders Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), and Merck (NYSE:MRK) collectively spend 13.8% of revenue on R&D.

The acquisition strategy can lead to some issues with accounting. Mr. Grant cites one instance where Valeant changed the revenue recognition policy of Medicis after acquiring the company in 2012. Valeant also focuses on cash earnings per share, which excludes things like acquisition-related costs. When looking at Valeant’s earnings according to generally accepted accounting principles (GAAP), the company actually is losing money.

In fact, Valeant uses many accounting metrics that do not conform to GAAP. The most recent quarterly call cited measures such as adjusted cash flow from operations and pro-forma same-store sales, among others. The problem is that management has complete discretion on how performance is measured. This can lead to abuse.

But this exact thesis could have been made years ago, and it would not have been good advice at all. The stock is up almost 10-fold over the past five years, and has more than doubled in the past year alone. Conversely, Jim Grant could argue that the skyrocketing shares are now much more overvalued than ever before.

Foolish bottom line

As mentioned previously, an investment in Valeant requires placing an enormous trust in management. The management team not only has discretion on which direction to take the company in, but also how to report progress. And if this discretion is abused, investors will pay a dear price.

Of course the exact same thing could have been said about Enron before it collapsed. In that case, Enron’s management did abuse its discretion, and manipulated manipulated earnings at will.

But betting against Valeant is a very risky move, one that would not have worked out well so far. And if Valeant’s leadership comes through for shareholders, Messrs. Grant and Chanos will be the ones paying a very steep price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. The Motley Fool owns shares of Johnson & Johnson.

More on Investing

Pile of Canadian dollar bills in various denominations
Tech Stocks

Where I’d Invest $1,000 in the TSX Today

You can get the best deal by investing $1,000 in the TSX’s next high-growth stock today.

Read more »

money goes up and down in balance
Dividend Stocks

Scotiabank: Buy, Sell, or Hold in 2025?

Bank of Nova Scotia is down 15% in 2025. Is the stock now oversold?

Read more »

dividend growth for passive income
Stocks for Beginners

Where to Invest $500 in 2 Growth Stocks for Beginners Starting Small

Beginning to invest has never been easier. Here are two growth stocks to buy with $500 for a long-term portfolio.

Read more »

Trans Alaska Pipeline with Autumn Colors
Energy Stocks

Why Enbridge Below $65 Could Be a Good Buy for Long-Term Investors

Enbridge is a blue-chip TSX dividend stock that offers you a tasty yield of 5.8% while trading at a discount…

Read more »

analyze data
Dividend Stocks

Market Correction Opportunity: 2 Canadian Dividend Stocks for TFSA Income

These stocks pay attractive yields today for income investors

Read more »

oil pump jack under night sky
Dividend Stocks

Here’s How Many Shares of TRP Stock to Own for $5,000 in Dividends, Even if Energy Prices Swing

Want major income, even if energy prices fluctuate, this could be a strong investment.

Read more »

A meter measures energy use.
Dividend Stocks

Here’s How to Earn $500/Month From Fortis Stock, Even With an Interest Rate Freeze

Fortis stock is a strong investment and can continue to be one even with interest rates remaining high.

Read more »

Person slides down a stair handrail
Stock Market

Beyond Steel and Aluminum: Unveiling the Hidden Tariff Casualties in Canada

While aluminum and steel tariffs grab headlines, Canadian investors overlook these real tariff victims: apparel, transport, and telecom stocks bleeding…

Read more »